Wendell Jones, Ph.D. | October 16, 2017

A Pan-Cancer view of gene expression in Immuno-Oncology with particular applications in ovarian cancer

Advantages of RNA-Seq for measurement of immune response
Over the last decade, there has been a great deal of renewed attention in immuno-oncology and genomic testing for cancer treatment. Therapies for cancer are being developed, approved, and administered that can either initiate, modulate, or enhance immune response to various cancers including metastatic cancer.

This presentation will examine the advantages of using RNA measurements of the tumor microenvironment to measure not only tumor-cell expression and related systems, but also the immune response (if any) to the tumor. Download this presentation to dive deeper into potential applications of immune subsystem-related biomarkers with ovarian cancer in prognostic areas such as predicting event-free and overall survival.

Wendell Jones, Ph.D., Principal Bioinformaticist and Scientific Advisor

Related Services:
Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach

New Opportunities for Immuno-oncology Clinical Development Programs through T cell/B cell Repertoire Profiling

Immune repertoire profiling provides better outcomes for immuno-oncology development programs

Gene expression for keeping pace with immuno-oncology breakthroughs and biomarker identification

When and how to use gene expression profiling

Read More